ArticleCancer imaging : the official publication of the International Cancer Imaging Society2025
PSMA-PET-derived distance features as biomarkers for predicting outcomes in primary prostate cancer post-radical prostatectomy.
Article in Cancer imaging : the official publication of the International Cancer Imaging Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Baseline Ga-68 PSMA PET/CT-derived volumetric parameters as predictors of biochemical recurrence following radical prostatectomy.Annals of nuclear medicine · 2026Article
- Limited incremental prognostic value of pretreatment MRI andAbdominal radiology (New York) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study aims to assess the predictive capability of PSMA-PET imaging for disease outcomes in primary prostate cancer post-radical prostatectomy. In addition to conventional lesion uptake measures, the evaluation includes the distance of lesion to the prostate to enhance risk stratification and outcome prediction.
methodsA cohort of 190 men diagnosed with primary prostate cancer and undergoing prostatectomy were initially screened, resulting in 103 patients meeting the selection criteria. Imaging parameters, including lesion SUVmax, primary metabolic tumor volume (PMTV), maximum distance from the lesion to the prostate (Dmax), and total distances from the lesion to the prostate (Dtotal), were extracted from 68Ga-PSMA-11 PET images. Findings were dichotomized based on primary lesion uptake, the tumor volume size, Dmax distance, and the presence of metastatic disease. Postoperative biochemical recurrence-free survival (BCRFS) was analyzed using Kaplan-Meier survival plots and Log-rank tests. Furthermore, univariate and multivariate Cox regression analyses were performed to evaluate the association of PET parameters with survival outcomes.
resultsClinical and histopathological characteristics were summarized, including age, weight, height, metastasis status, baseline PSA, biopsy Gleason score, pt stage, margin status, and lymph node status. After a median follow-up of 20 months, 66 events occurred, with the estimated 3-year BCRFS being 46%. Increased PSMA intensity (SUVmax > 17.06) was associated with less favorable BCRFS (log-rank p = 0.017). Increased primary metabolic tumor volume (PMTV > 41.59 cm
conclusionThe lesion distance to prostate was defined and assessed in conjunction with conventional PET parameters to facilitate preoperative risk stratification in primary prostate cancer following radical prostatectomy. The findings contribute to improved outcome prediction and emphasize the potential of PSMA-PET imaging in enhancing management strategies for prostate cancer patients. CLINICAL RELEVANCE: There is a critical need for non-invasive biomarkers that can predict treatment outcomes for patients with primary prostate cancer. Our study introduces the concept of using distance metrics, specifically the lesion distance to prostate in baseline PSMA-PET scans, to improve the prediction of biochemical recurrence following prostatectomy. These distance metrics consider the spatial distribution of lesions, offering a novel approach to assessing tumor spread and its implications for patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.